Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Equity: 2011-2025

Historic Return on Equity for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to -1.05%.

  • Myriad Genetics' Return on Equity fell 90.00% to -1.05% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.05%, marking a year-over-year decrease of 90.00%. This contributed to the annual value of -0.17% for FY2024, which is 14.00% up from last year.
  • As of Q3 2025, Myriad Genetics' Return on Equity stood at -1.05%, which was down 45.57% from -0.72% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Return on Equity ranged from a high of -0.01% in Q1 2022 and a low of -1.05% during Q3 2025.
  • Over the past 3 years, Myriad Genetics' median Return on Equity value was -0.30% (recorded in 2024), while the average stood at -0.36%.
  • As far as peak fluctuations go, Myriad Genetics' Return on Equity rose by 24bps in 2021, and later slumped by 90bps in 2025.
  • Myriad Genetics' Return on Equity (Quarterly) stood at -0.03% in 2021, then decreased by 10bps to -0.12% in 2022, then fell by 23bps to -0.36% in 2023, then rose by 18bps to -0.18% in 2024, then tumbled by 90bps to -1.05% in 2025.
  • Its Return on Equity was -1.05% in Q3 2025, compared to -0.72% in Q2 2025 and -0.14% in Q1 2025.